Compare Nutrien Ltd (NTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Nutrien Ltd trades at $67.3 (market cap $32.05B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: Nutrien Ltd is far larger — about 17.7× Recursion Pharmaceuticals Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NTR | RXRX | |
|---|---|---|
Market Cap | $32.05B | $1.81B |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $6.79 |
52-Week Low | $53.64 | $2.84 |
Enterprise Value | $43.86B | $1.33B |
Dividend Yield | 3.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
